Latest Breaking News On - Translational ocular immunology - Page 2 : comparemela.com

OKYO Pharma (OKYO) to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain

OKYO Pharma (OKYO) to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Garys jacobPedram hamrahPaul spencerPharma limited nasdaqCornea serviceTranslational ocular immunology at tufts medical centerTufts medical centerOkyo pharma limited nasdaqInvestigational new drugVice chairAcademic programsTranslational ocular immunologyTufts medicalAdvisory boardPrincipal investigatorChief executive

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain ( NCP ) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce a new agreement with Tufts Medical Center to conduct a 40-patient .

City ofUnited kingdomGarys jacobPedram hamrahPharma limited nasdaqTufts medical centerTranslational ocular immunology at tufts medical centerCornea servicePrincipal investigatorInvestigational new drugVice chairAcademic programsTranslational ocular immunologyTufts medicalAdvisory board

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

LONDON and NEW YORK, May 03, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet. | May 3, 2023

United kingdomSan diegoUnited statesCity ofPaul spencerRobert emmetGarys jacobPedram hamrahPharma limitedCornea serviceOptiva securitiesAmerican society of cataractLondon stock exchangeAmerican societyRefractive surgeryTranslational ocular immunology

OKYO Pharma to address key conference with data on dry eye drug

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), an ophthalmology-focused biopharmaceutical company, will showcase two presentations on its dry eye disease (DED).

United statesSan diegoPedram hamrahAmerican society of cataractEngland eye center at tufts medicalOkyo pharma ltdCornea serviceAmerican societyRefractive surgeryTranslational ocular immunologyNew england eye centerTufts medicalNeuropathic corneal pain

OKYO Pharma Ltd to address key conference with data on dry eye drug

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), an ophthalmology-focused biopharmaceutical company, will showcase two presentations on its dry eye disease (DED).

San diegoUnited statesPedram hamrahOkyo pharma ltdEngland eye center at tufts medicalCornea serviceAmerican society of cataractAmerican societyRefractive surgeryNeuropathic corneal painTranslational ocular immunologyNew england eye centerTufts medical